Wonderful post, nidan, and thanks for all of your insights. I remain firm in my belief that there is a common pathophysiological mechanism involving chronic neuroinflammation that, depending on age of onset, genotype, environmental variables, etc., result in many seemingly different neurological conditions. Anavex is the first to take this route in the approach to neurodegenerative conditions.
I look forward to the day where I foresee how 2-73 will advance clinical epileptology.